PIERIS PHARMACEUTICALS INC's ticker is PIRS and the CUSIP is 720795103. A total of 114 filers reported holding PIERIS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 45.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $14,000 | -99.4% | 12,477 | -99.0% | 0.00% | -100.0% |
| Q2 2022 | $2,258,000 | -38.3% | 1,207,316 | -0.1% | 0.01% | -20.0% |
| Q1 2022 | $3,661,000 | -34.4% | 1,208,226 | -18.1% | 0.01% | -37.5% |
| Q4 2021 | $5,578,000 | +234.8% | 1,475,778 | +358.0% | 0.02% | +220.0% |
| Q3 2021 | $1,666,000 | +45.8% | 322,241 | +8.0% | 0.01% | +25.0% |
| Q2 2021 | $1,143,000 | -45.1% | 298,363 | -63.2% | 0.00% | -50.0% |
| Q1 2021 | $2,082,000 | +22.1% | 810,140 | +18.8% | 0.01% | +14.3% |
| Q4 2020 | $1,705,000 | +21.4% | 681,957 | +0.6% | 0.01% | -12.5% |
| Q3 2020 | $1,404,000 | -10.7% | 678,038 | +33.6% | 0.01% | -20.0% |
| Q2 2020 | $1,573,000 | +15.2% | 507,500 | +24.5% | 0.01% | -23.1% |
| Q1 2019 | $1,366,000 | -33.3% | 407,783 | -47.0% | 0.01% | -43.5% |
| Q4 2018 | $2,047,000 | +153.3% | 769,551 | +433.7% | 0.02% | +187.5% |
| Q3 2018 | $808,000 | -13.5% | 144,200 | -21.7% | 0.01% | -27.3% |
| Q2 2018 | $934,000 | – | 184,248 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,360,000 | $6,895,000 | 5.06% |
| Omega Fund Management, LLC | 778,230 | $3,946,000 | 2.91% |
| BVF INC/IL | 5,346,838 | $27,108,000 | 2.65% |
| Virtus ETF Advisers LLC | 152,550 | $773,000 | 0.68% |
| SPHERA FUNDS MANAGEMENT LTD. | 842,632 | $4,272,000 | 0.59% |
| Tekla Capital Management LLC | 2,087,380 | $10,583,000 | 0.40% |
| Schonfeld Strategic Advisors LLC | 828,600 | $4,201,000 | 0.23% |
| Orbimed Advisors | 3,140,000 | $15,920,000 | 0.19% |
| Lombard Odier Asset Management (USA) Corp | 563,878 | $2,859,000 | 0.19% |
| Rhenman & Partners Asset Management AB | 300,000 | $1,521,000 | 0.16% |